Trial Profile
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Elacestrant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Sponsors Radius Health Inc.; Stemline Therapeutics
- 29 Jan 2021 Results published in the Journal of Clinical Oncology
- 04 May 2020 Status changed from active, no longer recruiting to completed.
- 09 Mar 2020 Planned End Date changed from 1 Jan 2020 to 1 Apr 2020.